Cargando…

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

PURPOSE: When during cancer treatment resistance to a tyrosine kinase inhibitor (TKI) occurs, switching to another TKI is often considered as a reasonable option. Previously, we reported that resistance to sunitinib may be caused by increased lysosomal sequestration, leading to increased intracellul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555235/ https://www.ncbi.nlm.nih.gov/pubmed/25665527 http://dx.doi.org/10.1007/s13402-015-0218-8

Ejemplares similares

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
por: Azijli, Kaamar, et al.
Publicado: (2015)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
por: Gotink, Kristy J., et al.
Publicado: (2009)

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
por: Walraven, Maudy, et al.
Publicado: (2018)

Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
por: Rovithi, Maria, et al.
Publicado: (2017)

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2022)

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
por: Adema, Auke D., et al.
Publicado: (2011)

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
por: Kleibeuker, Esther A, et al.
Publicado: (2015)

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors
por: Gerritse, Sophie L., et al.
Publicado: (2022)

Combining radiotherapy with sunitinib: lessons (to be) learned
por: Kleibeuker, Esther A., et al.
Publicado: (2015)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018)

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
por: Mammatas, L. H., et al.
Publicado: (2020)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
por: Que, Yi, et al.
Publicado: (2018)

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
por: Labots, Mariette, et al.
Publicado: (2020)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
por: Maillard, Maud, et al.
Publicado: (2022)

Effects of Cancer Presence and Therapy on the Platelet Proteome
por: Walraven, Maudy, et al.
Publicado: (2021)

Sorafenib and sunitinib: A dermatologist's perspective
por: Pragasam, Vijendran, et al.
Publicado: (2014)

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer
por: van der Mijn, Johannes C., et al.
Publicado: (2014)

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
por: Mitchell, Catherine C, et al.
Publicado: (2014)

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
por: Santoni, M, et al.
Publicado: (2013)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer
por: Poel, Dennis, et al.
Publicado: (2020)

Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer
por: Poel, Dennis, et al.
Publicado: (2018)

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib
por: MacLean, Elizabeth, et al.
Publicado: (2016)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics
por: van der Wijngaart, Hanneke, et al.
Publicado: (2023)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

CD133(+) circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
por: Vroling, L, et al.
Publicado: (2010)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
por: Van Der Steen, Nele, et al.
Publicado: (2020)

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
por: Lipplaa, Astrid, et al.
Publicado: (2016)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
por: Wentink, Madelon Q, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5jrte54bcfpotkpermbeghi9ld